Indaptus Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
INDP Nasdaq 2830 indaptusrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Indaptus Therapeutics, Inc.

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - Dec 29th, 2025 5:00 am
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit - Nov 17th, 2025 6:00 am
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 6:30 am
Wall Street Set to Open Higher Friday; Nonfarm Payrolls Fall Well Short of Forecasts - Sep 5th, 2025 7:22 am
Indaptus Therapeutics Provides Clinical Update - Sep 4th, 2025 2:01 pm
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference - Sep 2nd, 2025 2:05 pm
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 6:00 am
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants - Jul 1st, 2025 6:14 am
Indaptus Therapeutics Announces Reverse Stock Split - Jun 25th, 2025 5:00 am
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - Jun 13th, 2025 6:00 am
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - Jun 2nd, 2025 6:00 am
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 14th, 2025 6:00 am
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - May 8th, 2025 6:00 am
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - Mar 25th, 2025 6:00 am
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 - Mar 20th, 2025 6:00 am
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - Mar 18th, 2025 6:00 am
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - Mar 13th, 2025 5:30 am
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Mar 12th, 2025 2:15 pm
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - Mar 4th, 2025 6:00 am
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - Feb 25th, 2025 6:00 am